Evaluating the post-licensure effectiveness of a group B meningococcal vaccine in New Zealand: a multi-faceted strategy

被引:14
作者
Ameratunga, S
Macmillan, A
Stewart, J
Scott, D
Mulholland, K
Crengle, S
机构
[1] Univ Auckland, Fac Med & Hlth Sci, Sch Populat Hlth, Epidemiol & Biostat Sect, Auckland, New Zealand
[2] Univ Melbourne, Parkville, Vic 3052, Australia
关键词
meningococcal disease; vaccine; product surveillance; postmarketing; immunization programs; epidemiologic methods; effectiveness;
D O I
10.1016/j.vaccine.2005.01.048
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
A nationwide strategy to control a group B meningococcal disease epidemic in New Zealand using an epidemic strain-specific vaccine (MeNZB (TM)) commenced in 2004. In the absence of randomised controlled trials investigating the efficacy of this particular vaccine, a complement of observational methods are planned to evaluate the post-licensure effectiveness of this vaccine strategy. The two main approaches involve a Poisson regression model investigating the overall impact of the MeNZB (TM) programme on disease rates over time capitalising on detailed population-based disease surveillance data and the staged roll-out of the vaccine campaign, and a case-control study that aims to estimate vaccine effectiveness in pre-school children. The studies are designed to minimise the potential biases inherent in all observational methods and provide critical data on the effectiveness of a major public health intervention. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2231 / 2234
页数:4
相关论文
共 11 条
[1]
Household crowding a major risk factor for epidemic meningococcal disease in Auckland children [J].
Baker, M ;
McNicholas, A ;
Garrett, N ;
Fafphm, NJ ;
Stewart, J ;
Koberstein, V ;
Lennon, D .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (10) :983-990
[2]
ESTIMATION OF VACCINE EFFECTIVENESS USING THE SCREENING METHOD [J].
FARRINGTON, CP .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1993, 22 (04) :742-746
[3]
Design and interpretation of vaccine field studies [J].
Halloran, ME ;
Longini, IM ;
Struchiner, CJ .
EPIDEMIOLOGIC REVIEWS, 1999, 21 (01) :73-88
[4]
Jefferies C, 1999, NEW ZEAL MED J, V112, P115
[5]
MARTIN D, 2004, EPIDEMIOLOGY MENINGO
[6]
New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4 [J].
Martin, DR ;
Walker, SJ ;
Baker, MG ;
Lennon, DR .
JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (02) :497-500
[7]
McCullagh P., 2018, Generalized Linear Models
[8]
Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story [J].
Miller, E ;
Salisbury, D ;
Ramsay, M .
VACCINE, 2001, 20 :S58-S67
[9]
Effectiveness of BC meningococcal vaccine in Brazil [J].
Nishioka, SD .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1996, 25 (05) :1102-1103
[10]
ASSESSMENT OF THE DIRECT EFFECTIVENESS OF BC MENINGOCOCCAL VACCINE IN RIO-DE-JANEIRO, BRAZIL - A CASE-CONTROL STUDY [J].
NORONHA, CP ;
STRUCHINER, CJ ;
HALLORAN, ME .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1995, 24 (05) :1050-1057